RightFit
RecruitingPhase not listed

Hyperpolarized 129-Xenon Imaging in Adult Hematopoietic Cell Transplant Recipients With Pulmonary Impairment

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

  • Procedures mentioned: MRI scans

Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.

Show the study's own words
  • "A secondary objective is to determine whether measurement of 129-Xe MRI characteristics in patients with BOS stage 0p can predict BOS progression 6 months after enrollment."
Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests how well a special xenon MRI scan measures lung function compared with breathing tests and CT scans. It also checks whether the MRI can predict worsening lung problems after 6 months. It is for adults who had a blood-forming cell transplant from a donor and have certain transplant-related problems, plus healthy adults who help check the scanner.

This study is designed to measure the correlation of hyperpolarized 129-Xe magnetic resonance imaging (129-XeMRI) in allogeneic hematopoietic cell transplant (allo-HCT) recipients at MD Anderson Cancer Center (MDACC) who develop bronchiolitis obliterans syndrome (BOS) or BOS stage 0p (pulmonary impairment not meeting the definition for BOS, defined below) and controls with chronic graft-versus-host disease (cGVHD). The primary objective of the study is to correlate 129-Xenon measures of ventilation, gas exchange, and pulmonary circulation with spirometric and quantitative CT measurements. A secondary objective is to determine whether measurement of 129-Xe MRI characteristics in patients with BOS stage 0p can predict BOS progression 6 months after enrollment.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Be age 18 or older.
  • For the transplant group: Have had a blood-forming cell transplant from a donor.
  • Have bronchiolitis obliterans syndrome (BOS), a condition that damages small airways; early lung problems called BOS stage 0p; or chronic graft-versus-host disease outside the lungs with no lung problems. Graft-versus-host disease happens when donor cells attack your body.
  • For the healthy volunteer group: Have no medical problems. Volunteers have only the xenon MRI to help check the scanner.
  • Study team members may be healthy volunteers if they have no past lung disease.

Who can't join

  • Cannot return to MD Anderson for regular medical care.
  • Cannot or do not want to give informed consent, which means agreeing to join after learning about the study.
  • Have a disease that has come back, or are expected to live less than 6 months when joining.
  • Have a fear of tight spaces so severe that you cannot have an MRI.
  • Have a current lung infection.
  • Are pregnant.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: \- Allo-HCT recipients who are at least 18 years of age and have BOS (n=10 patients), BOS 0p (n = 10 patients), or cGVHD of a non-lung organ without evidence of pulmonary impairment (n = 5 patients). Healthy Cohort - Inclusion Criteria: We will perform only XeMRI imaging on 10 healthy adult (18 years and older) volunteers with no medical issues for technical calibration of the XeMRI technology. Members of the study team may serve as healthy volunteers if they have no prior history of lung disease. These data will not be included as part of the analysis. Exclusion Criteria: 1. Participants unable to follow up at MD Anderson for routine clinical care 2. Inability or unwillingness to give informed consent 3. Relapsed disease or life expectancy less than 6 months at time of enrollment 4. Severe claustrophobia precluding MRI imaging 5. Active pulmonary infection 6. Pregnant women

Study sites (1)

TX